BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 31365695)

  • 1. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
    Andrade FM; Oliveira AD; Lopes AJ
    Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
    Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of the COPD Assessment Test to evaluate the lung-specific quality of life in systemic sclerosis-associated interstitial lung disease.
    Mugii N; Someya F
    Clin Respir J; 2020 Jun; 14(6):527-532. PubMed ID: 32045097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventilation distribution and small airway function in patients with systemic sclerosis.
    Silva BRA; Rufino R; Costa CH; Vilela VS; Levy RA; Lopes AJ
    Rev Port Pneumol (2006); 2017; 23(3):132-138. PubMed ID: 28258938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between ventilation heterogeneity and exercise intolerance in adults with sickle cell anemia.
    Lopes AJ; Marinho CL; Alves UD; Gonçalves CEA; Silva PO; Botelho EC; Bedirian R; Soares AR; Maioli MCP
    Braz J Med Biol Res; 2017 Jul; 50(8):e6512. PubMed ID: 28746470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
    Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
    PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
    Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
    Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
    Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
    Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing.
    Martis N; Queyrel-Moranne V; Launay D; Neviere R; Fuzibet JG; Marquette CH; Leroy S
    J Rheumatol; 2018 Jan; 45(1):95-102. PubMed ID: 29093153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.
    Buch MH; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells AU; Matucci-Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM; Seibold JR
    Ann Rheum Dis; 2007 Feb; 66(2):169-73. PubMed ID: 16868020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
    Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
    Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
    Int J Cardiol; 2016 Jun; 212():265-73. PubMed ID: 27057932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?
    Sobiecka M; Lewandowska K; Kober J; Franczuk M; Skoczylas A; Tomkowski W; Kuś J; Szturmowicz M
    Lung; 2020 Jun; 198(3):547-554. PubMed ID: 32206858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
    Fischer A; Swigris JJ; Bolster MB; Chung L; Csuka ME; Domsic R; Frech T; Hinchcliff M; Hsu V; Hummers LK; Gomberg-Maitland M; Mathai SC; Simms R; Steen VD
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-109-14. PubMed ID: 25372796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
    Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.